Physician profile
Nirav R Patel
NPI 1639339336
$1,834.50
in general payments reported to CMS, 2019-2025
15 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $60.40 · 2021: $141 · 2022: $160 · 2023: $357 · 2024: $361 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $364.04 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $262.43 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $248.03 | 2019-2023 | Sucraid |
| Genzyme Corporation | $235.06 | 2022-2025 | |
| Janssen Biotech, INC. | $167.65 | 2019-2025 | Stelara, Tremfya |
| Merck Sharp & Dohme LLC | $128.38 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $123.56 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.04 | 2021-2025 | Gattex |
| Organon LLC | $50.40 | 2023-2025 | Renflexis, Hadlima |
| Biocon Biologics INC | $39.72 | 2024 | Hulio |
| Alexion Pharmaceuticals, INC. | $38.76 | 2019 | |
| Albireo Pharma, INC. | $28.18 | 2022 | |
| Amgen INC. | $27.91 | 2023 | Amjevita, Avsola |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.77 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.